RECURRENT ACUTE BIPHENOTYPIC LEUKEMIA
Clinical trials for RECURRENT ACUTE BIPHENOTYPIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT ACUTE BIPHENOTYPIC LEUKEMIA trials appear
Sign up with your email to follow new studies for RECURRENT ACUTE BIPHENOTYPIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising combo for tough leukemias hits snag: trial ends early
Disease control TerminatedThis phase II trial tested a combination of two drugs, venetoclax and decitabine, in 235 patients with certain blood cancers like acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) that had come back or not responded to treatment, as well as in older patien…
Matched conditions: RECURRENT ACUTE BIPHENOTYPIC LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Promising combo for tough leukemia hits roadblock: trial stopped early
Disease control TerminatedThis early-phase trial tested a combination of two drugs, omacetaxine and venetoclax, in 24 adults with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that had a specific genetic change called RUNX1. The goal was to find the best dose and se…
Matched conditions: RECURRENT ACUTE BIPHENOTYPIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC